Financial Data and Key Metrics Changes - The operating revenue for Q1 2025 was $9,095.2 million, up 1% from the previous quarter but down less than 1% year-over-year [14] - Units delivered were 494,509, representing a 5% decrease, while revenue per unit, excluding fuel surcharge, was approximately $177, down about 9% from Q1 2024 [15] - The company had approximately $10,900 million in cash and equivalents at the end of Q1 2025, with an aggregate debt balance of approximately $79,200 million [17] Business Line Data and Key Metrics Changes - The dedicated fleet service generated revenue of $4,300 million in Q1 2025, up from $3,400 million in Q4 2024 but down 33% from $6,400 million in Q1 2024 [15] - Revenue from spot opportunities comprised 4.3% of total revenue at approximately $3,700 million, unchanged from Q4 2024 but down from $13,800 million in Q1 2024 [16] Market Data and Key Metrics Changes - Industry sales were strong in March 2025, with auto SAAR reaching 17,800,000 units, the highest since April 2021 [9] - Analysts have reduced their full-year projected SAAR for 2025, with Goldman Sachs projecting 15,400,000 units, down from 16,300,000 [10] Company Strategy and Development Direction - The company aims to increase market share and effectively integrate merged operations to drive improved efficiency and profitability [11] - The acquisition of Brothers Auto Transport is expected to enhance the company's presence in the Northeast and Mid Atlantic regions, providing new load-sharing opportunities [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the uncertain economic environment and emphasized the importance of adapting to changes in the automotive supply chain [11] - Despite expectations for a weaker market, the company anticipates growth in total revenue in the high single digits for Q2 2025 [18] Other Important Information - The company expects approximately $15 million in CapEx for revenue-generating equipment in 2025, contingent on market conditions [17] - The integration of Brothers Auto Transport is progressing smoothly, with plans to unify systems and processes by July 1, 2025 [13] Q&A Session Summary Question: Market changes and earnings power - Management acknowledged the uncertain outlook but noted record revenue in April, suggesting potential for improved earnings power even in a challenging market [22] Question: Customer behavior in response to tariffs - OEMs are taking varied actions, with some continuing business as usual while others are holding back production due to tariff uncertainties [24] Question: Mix of domestic vs. imported vehicles - The company estimates a mix of approximately 60% domestic and 40% imported vehicles, with regional variations [32] Question: Revenue from Brothers Auto Transport - Brothers Auto Transport is expected to contribute approximately $60 million in annualized revenue, ramping up from mid-Q1 2025 [38] Question: Q2 revenue and EBITDA expectations - Management projected high single-digit sequential growth in revenue for Q2, with corresponding improvements in EBITDA [40]

Core Viewpoint - Pharmaceutical companies are resisting Trump's plan, citing concerns that tariff threats hinder further investment in R&D and manufacturing in the U.S. [1][2] Group 1: Company Responses - Pfizer's CEO Albert Bourla stated that tariff threats are obstructing the company's ability to invest in R&D and manufacturing in the U.S. [2] - Eli Lilly's CEO Dave Ricks expressed skepticism that tariffs would address national security concerns surrounding the U.S. drug supply chain [2]. Group 2: Industry Trends - The U.S. pharmaceutical manufacturing sector has significantly shrunk over the past few decades, with most active pharmaceutical ingredient production moving to countries like China due to lower labor and production costs [2]. - Approximately 90% of prescription drugs in the U.S. are basic generics, which are difficult to produce domestically due to low prices [2]. Group 3: Economic Implications - Imposing tariffs on generics, which have much lower profit margins than brand-name drugs, could force some generic manufacturers to exit the U.S. market, potentially exacerbating shortages of essential drugs like sterile injectables [2]. - In 2023, the U.S. imported over $200 billion worth of drugs, with 73% coming from Europe, primarily from Ireland, Germany, and Switzerland [2]. - Establishing drug manufacturing facilities in the U.S. may increase production costs and drug prices, raising concerns about drug affordability [2].